EBS Q2 2018 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$433M

Q2 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$220M+118.5% YoY

Gross Profit

$110M50.0% margin

Operating Income

$67M30.3% margin

Net Income

$50M22.8% margin

EPS (Diluted)

$0.98

QoQ Revenue Growth

+86.9%

Cash Flow

Operating Cash Flow

$35M

Free Cash Flow

$21M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$201M

Stockholders' Equity

$938M

Cash & Equivalents

$190M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$220M	$101M	+118.5%
Gross Profit	$110M	$41M	+171.4%
Operating Income	$67M	$9M	+683.2%
Net Income	$50M	$5M	+985.4%